Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Guangzhou Institute of Respiratory Disease
Our primary goal was to determine whether LTD4-BPT could be a clear indicator for assessing efficacy of LTRA. Logistic regression model was adopted for statistical analysis. In this model, pre-treatment PD20FEV1-LTD4 represented anticipated efficacy. The median of PD20FEV1-LTD4 was used for classification of asthmatics, with a lower figure representing a better anticipated outcome. Various variables, including the difference in pre- and post- treatment FENO, PEFmax, PEFmin, PEFR, PD20FEV1 and asthma scores, were introduced in the model representing the actual efficacy of LTRA. We aimed to test whether there would be certain parameters that assist prediction of anticipated outcome.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
subjects aged between 18 and 65,without acute upper respiratory tract infection for the past 2 weeks
had a normal chest radiographic result
had a baseline spirometry with the forced expiratory volume in one second (FEV1) of not less than 60% predicted
had withheld leukotriene receptor antagonists (LTRA) for over 5 days
oral glucocorticosteroid or anti-histamine for 3 days
oral xanthenes or long-acting bronchodilators for 2 days
inhaled corticosteroid or long-acting bronchodilator for a day as well as short-acting bronchodilator for 4 hours prior to the measurement
You may not be if
subjects had a fall of no less than 15% in FEV1 after repetitive forced respiration or a fall of no less than 20% in FEV1 after the inhalation of ethanol diluent control
had a past confirmed history of respiratory disease other than bronchial asthma (COPD, bronchiectasis, pulmonary thromboembolism, etc.) or other severe systemic disease(myocardial infarction, malignant tumor, etc.)
had a poor cooperation to the test or limited understandings, were immunocompromised, or had participated other clinical trials for the past 3 months.